See more : Poseidon Nickel Limited (PSDNF) Income Statement Analysis – Financial Results
Complete financial analysis of Seer, Inc. (SEER) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Seer, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
- Tourmaline Oil Corp. (TOU.TO) Income Statement Analysis – Financial Results
- Investeringsforeningen Nordea Invest – Global Small Cap Enhanced (NDIGSEKL1.CO) Income Statement Analysis – Financial Results
- Adams Natural Resources Fund, Inc. (PEO) Income Statement Analysis – Financial Results
- Transcendent Group AB (publ) (TRG.ST) Income Statement Analysis – Financial Results
- JZ Capital 2021 6% CULS (JZCC.L) Income Statement Analysis – Financial Results
Seer, Inc. (SEER)
About Seer, Inc.
Seer, Inc., a life sciences company, engages in developing and commercializing products to decode the secrets of the proteome. It develops Proteograph Product Suite, an integrated solution that comprises consumables, an automation instrumentation, and software that allows researchers to conduct proteomic studies in therapeutic and diagnostic research, and clinical trials. The company intends to sell its products for research purposes, which cover academic institutions, life sciences, and research laboratories, as well as biopharmaceutical and biotechnology companies for non-diagnostic and non-clinical purposes. It has a collaboration agreement with Discovery Life Sciences, LLC. and the Salk Institute for Biological Studies. The company was formerly known as Seer Biosciences, Inc. and changed its name to Seer, Inc. in July 2018. Seer, Inc. was incorporated in 2017 and is headquartered in Redwood City, California.
Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
---|---|---|---|---|---|---|
Revenue | 15.18M | 14.69M | 6.39M | 656.00K | 58.00K | 0.00 |
Cost of Revenue | 8.16M | 7.94M | 3.21M | 0.00 | 701.00K | 100.00K |
Gross Profit | 7.03M | 6.74M | 3.19M | 656.00K | -643.00K | -100.00K |
Gross Profit Ratio | 46.29% | 45.91% | 49.87% | 100.00% | -1,108.62% | 0.00% |
Research & Development | 53.02M | 45.80M | 29.12M | 18.94M | 12.39M | 3.78M |
General & Administrative | 0.00 | 0.00 | 0.00 | 15.36M | 4.61M | 2.98M |
Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
SG&A | 58.95M | 58.53M | 45.76M | 15.36M | 4.61M | 2.98M |
Other Expenses | 0.00 | -351.00K | -223.00K | -9.00K | -58.00K | 0.00 |
Operating Expenses | 111.97M | 103.98M | 74.66M | 34.31M | 16.94M | 6.76M |
Cost & Expenses | 120.12M | 111.92M | 77.87M | 34.31M | 16.94M | 6.76M |
Interest Income | 17.76M | 4.60M | 326.00K | 883.00K | 850.00K | 451.00K |
Interest Expense | 0.00 | 327.00K | 22.00K | 9.00K | 5.00K | 0.00 |
Depreciation & Amortization | 5.58M | 5.90M | 3.56M | 1.61M | 701.00K | 100.00K |
EBITDA | -97.89M | -93.29M | -68.59M | -31.17M | -15.33M | -6.21M |
EBITDA Ratio | -644.74% | -633.07% | -1,112.72% | -4,994.82% | -26,434.48% | 0.00% |
Operating Income | -103.46M | -97.24M | -71.47M | -33.65M | -16.88M | -6.76M |
Operating Income Ratio | -681.48% | -662.14% | -1,117.81% | -5,129.42% | -29,108.62% | 0.00% |
Total Other Income/Expenses | 17.19M | 4.27M | 304.00K | 874.00K | 845.00K | 451.00K |
Income Before Tax | -86.28M | -92.97M | -71.17M | -32.78M | -16.04M | -6.31M |
Income Before Tax Ratio | -568.28% | -633.07% | -1,113.06% | -4,996.19% | -27,651.72% | 0.00% |
Income Tax Expense | 0.00 | -4.27M | -2.54M | -1.61M | 5.00K | 451.00K |
Net Income | -86.28M | -88.70M | -68.63M | -31.17M | -16.04M | -6.31M |
Net Income Ratio | -568.28% | -604.00% | -1,073.40% | -4,751.37% | -27,660.34% | 0.00% |
EPS | -1.35 | -1.42 | -1.13 | -0.51 | -0.26 | -0.29 |
EPS Diluted | -1.35 | -1.42 | -1.13 | -0.51 | -0.26 | -0.29 |
Weighted Avg Shares Out | 63.85M | 62.43M | 60.86M | 60.91M | 60.91M | 21.45M |
Weighted Avg Shares Out (Dil) | 63.85M | 62.43M | 60.86M | 60.91M | 60.91M | 21.45M |
Biotech IPOs Stay Hot With Seer, Silverback Set To Trade
Source: https://incomestatements.info
Category: Stock Reports